linjc16/ctgov huggingface dataset:
To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population

Study Overview
=================
Brief Summary
-----------------
Double-blind, randomized, controlled, cross-over design with 3 test products and one control product. To evaluate the effect of 4 different flour compositions (guar gum 2% and 4%, chickpea flour 15% and barley flour 2% and 5%) of selected fibres and flours, on post-prandial plasma (PPG) and serum insulin levels in healthy Indian subjects, after the consumption of flat bread made from 100 gram of flour compositions.

Official Title
-----------------
To Evaluate the Effect of 4 Different Flour Compositions of Selected Fibres and Flours, on Post-prandial Plasma Glucose (PPG) and Serum Insulin Levels in Normal Indian Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Control (market standard)
* Other: wheat flour
* Other: chickpea flour
* Other: guar gum
* Other: barley


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female subjects between > 20 and < 50 years of age BMI of >18 and < 23 kg/m2 Fasting blood glucose value of volunteer is > 3.4 and <6.1 mmol/litre (i.e. 62- 110 mg/dl) at screening Exclusion Criteria: Chronic smokers, tobacco chewers and drinkers.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control (market standard)<br>100 g wheat flour (atta) | Other: Control (market standard)<br> <br> |
| Active Comparator: High fibre 1<br>81% wheat flour (atta) + 15% chickpea + 4% guar gum | Other: wheat flour<br> <br> Other: chickpea flour<br> <br> Other: guar gum<br> <br> |
| Active Comparator: High fibre 2<br>80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley | Other: wheat flour<br> <br> Other: chickpea flour<br> <br> Other: guar gum<br> <br> Other: barley<br> <br> |
| Active Comparator: High fibre 3<br>77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley | Other: wheat flour<br> <br> Other: chickpea flour<br> <br> Other: guar gum<br> <br> Other: barley<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive incremental area under blood glucose curve |  | 0-120 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total area under the serum insulin curve |  | 0-120 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood glucose, serum insulin
Treatment and Complication of Bath PUVA in Vitiligo

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether bath PUVA are effective in treatment of vitiligo and what is the complication of bath PUVA in vitiligo.

Official Title
-----------------
Treatment and Complication of Bath PUVA in Vitiligo

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Device: Bath PUVA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vitiligo Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Bath PUVA|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bath PUVA
Effects of Plant Extracts on Semen Quality

Study Overview
=================
Brief Summary
-----------------
this is a prospective randomized placebo-controlled double-blinded trial investigating the effect of plant extracts from Alpinia galanga and Punica granatum on human semen quality. The investigators hypothesize that these plant extracts will improve semen quality.

Official Title
-----------------
An Extract of Pomegranate Fruit and Galangal Rhizome Increases the Numbers of Motile Sperm: A Prospective, Randomised, Controlled, Double-Blinded Trial

Conditions
-----------------
Poor Semen Quality

Intervention / Treatment
-----------------
* Dietary Supplement: Extracts of Punica granatum and Alpinia galanga
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Reduced semen quality Exclusion Criteria: Total count of motile sperm less than 1 million sperm/ejaculate or more than 200 million sperm/ejaculate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Plant extracts<br> | Dietary Supplement: Extracts of Punica granatum and Alpinia galanga<br>* Tablets, two in the morning and two in the evening<br>|
| Placebo Comparator: Placebo<br> | Dietary Supplement: Placebo<br>* Tablets, two in the morning and two in the evening<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Count of motile sperm per ejaculate |  | Each participant is given plant extract for three months with flanking semen analyses. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphology: percentage of morphologically abnormal sperm in the ejaculate | If we find an increase in the primary outcome measure in data from participants receiving plant extracts and not in those receiving placebo tablets, we wish to further investigate whether sperm morphology also improves when consuming the plant extracts, e.g. whether the percentage of abnormal sperm in an ejaculate decreases in the group of participants receiving the active plant extracts | Each participant is given plant extract for three months with flanking semen analyses. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Semen quality, Plant extracts
Ultrasound for Confirmation of Gastric Tube Placement in Critically Ill Patients Under Invasive Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
Introduction: Data using ultrasonography to confirm correct position of the gastric tube is heterogeneous in approach sites, combination exams, and methodology. Aim: Find the best strategy to confirm gastric tube placement to avoid immediate complication. Method: A randomized controlled trial was initiated to compare ultrasonography and standard routine method, using non-inferiority design. The study will be conducted in one medical ICU with 59 beds at a medical center. The primary outcome is the correct rate as comparing with the chest radiography in each group. Total 190 patients is needed with estimated 10% drop-out rate.

Official Title
-----------------
Ultrasound for Confirmation of Gastric Tube Placement in Critically Ill Patients Under Invasive Mechanical Ventilation, a Randomization Trial

Conditions
-----------------
Ultrasound for Confirmation of Gastric Tube Placement in Critically Ill Patients Under Invasive Mechanical Ventilation

Intervention / Treatment
-----------------
* Diagnostic Test: ultrasonography (US)
* Diagnostic Test: Standard routine (SR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical indication of nasogastric tube placement Age than 20 years old. Exclusion criteria: Facial trauma or head-base fractures Esophageal or gastric resection Esophageal strictures or alkaline injury Open wound in the area to prevent ultrasonography

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ultrasonography (US)<br> | Diagnostic Test: ultrasonography (US)<br>* US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.<br>|
| Active Comparator: Standard routine (SR)<br> | Diagnostic Test: Standard routine (SR)<br>* Standard routine (SR)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correct rate as comparing with the chest radiography in each group |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| procedure time, tube placement confirmation time other than chest radiography method, and additional auscultation method in US group |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Point-of-care ultrasound,ultrasound
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.

Official Title
-----------------
A Double-Blind, Randomized, Active-Controlled MK0767 and Metformin Comparator Study in Type 2 Diabetic Patients Inadequately Controlled on Diet and Exercise

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: MK0767
* Drug: Comparator: placebo (unspecified)
* Drug: Comparator: metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients are men and non-pregnant women ages 21 to 78 years Patients either not on antihyperglycemic medications (>8 weeks), or being treated with a single oral antihyperglycemic agent & willing to discontinue therapy for the duration of the study Exclusion Criteria: Patient has history of type 1 diabetes mellitus and or history of ketoacidosis Patients undergoing surgery within 30 days of Visit 1 Patients taking Warfin or Warfin-like anticoagulants Patients on a weight loss program with on-going weight loss or starting an intensive exercise program within 4 weeks of Visit 1/Week 9

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0767|Duration of Treatment: 52 Weeks|
|Drug: Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks|
|Drug: Comparator: metformin|Duration of Treatment: 52 Weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This study will assess the lipid lowering effectiveness of MK0767 compared to metformin over the course of 52 weeks. |  | over the course of 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MK0767 will be safe and well tolerated. |  | over the course of 52 weeks |
Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.

Official Title
-----------------
Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Conditions
-----------------
T Cell Lymphoma

Intervention / Treatment
-----------------
* Drug: Endostar and CHOPT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female aged 18 to 70 years old. Diagnosis of T cell lymphoma according to WHO Classification, without antitumor therapy At least 1 measurable tumor mass (greater than 1.5cm in the longest dimension and greater than 1.0 in the short axis) Eastern Cooperative Oncology Group status 0-2 White blood cell≥4.0×109cells/L; Absolute neutrophil count (ANC) ≥1.5×109cells /L; Platelets≥100×109cells/L Alanine transaminase (ALT) ≤2×upper limit of normal(ULN); Aspartate transaminase (AST) ≤2×ULN; Total Bilirubin≤1.5×ULN; Creatinine in normal range Exclusion Criteria: No active central nervous system lymphoma or brain tumor Suppurative inflammation,Chronic infection Severe heart disease, conclusion: congestive heart failure; uncontrolled cardiac arrhythmia; myocardial infarction; refractory hypertension psychiatric history Primary cutaneous T cell lymphoma Pregnant or lactating women Concurrent treatment with another investigational agent Accept radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endostar<br>CHOPT chemotherapy plus Endostar | Drug: Endostar and CHOPT<br>* Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone<br>* Other names: Endostatin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy including overall response rate, progression free survival and overall survival | According to International Workshop Criteria, the number of participants with complete remission, partial remission and stable disease as a measure of efficacy.progressive free survival and overall survival of the participants are the second measure of efficacy | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety of Endostar combined with CHOPT chemotherapy | Number of participants with adverse events as a measure of safety | 1 year |
Medical Dispatchers' Perception of Visual Information in Real Out-of-hospital Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
Dispatcher-assisted cardiopulmonary resuscitation is a complex, nonvisual procedure that is challenging for the dispatcher. The aim was to explore the medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.

Detailed Description
-----------------
Ten individual interviews with medical dispatchers who had previously handled an emergency call concerning OHCA captured on closed-circuit television (CCTV) were conducted. First, the medical dispatcher listened to the emergency call and described their perception of the scenario. Afterward, the CCTV recording was shown to the dispatcher, who was then interviewed. The interviews were videotaped, and the audio files were transcribed verbatim. Thematic content analysis was conducted.

Official Title
-----------------
Medical Dispatchers' Perception of Visual Information in Real Out-of-hospital Cardiac Arrest: A Qualitative Interview Study

Conditions
-----------------
Out-Of-Hospital Cardiac Arrest

Intervention / Treatment
-----------------
* Other: CCTV footage to the medical dispatcher in OHCA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency Medical dispatchers who had previously handled an emergency call concerning OHCA captured on closed-circuit television (CCTV) Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The added value of visual information to the medical dispatcher in out-of-hospital cardiac arrests (OHCA) situations. | We applied a qualitative research methodology using thematic analysis with an explorative and inductive approach. The first author followed Braun and Clarke's six-step analytical approach, which has the following steps: familiarising with data, generating initial codes, searching for themes, reviewing themes, defining and naming themes, and producing the report. Codes and themes were organised using Nvivo10 software (QSR International Pty Ltd, Australia). Analysis continued until saturation; that is, when information became redundant. | One hour interview with earch of the emergency medical dispathers | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dispatcher-assisted cardiopulmonary resuscitation, Out-Of-Hospital Cardiac Arrest, Emergency Medical dispatcher
Nis Register Study Comparing Seroquel and Seroquel Prolong

Study Overview
=================
Brief Summary
-----------------
The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The primary objectives of the study are:1.To collect information on the used Quetiapine Immediate Release or Quetiapine Extended Release medication 2.To collect information on duration and number of hospitalisation days 3.Change of GAF points

Official Title
-----------------
A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.

Conditions
-----------------
Comparing Hospitalisation Time With Seroquel and Seroquel Prolong

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medication: Seroquel or Seroquel Prolong Diagnosis: F20-F29 or F30-F31 (ICD-10) In-patient Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Seroquel | |
| 2<br>Seroquel Prolong | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalisation time |  | 2008-2010 | 
| Treatment practice |  | 2008-2010 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary diagnosis |  | 2008-2010 | 
| Medication at the end of hospitalisation |  | 2008-2010 | 
| GAF rating points |  | 2008-2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, Bipolar Disorder, Manic Disorder, Register study, Quetiapine, Quetiapine Prolong, Seroquel, Seroquel Prolong, Seroquel XR, In-patient
Prevalence of Ocular Surface Disease in Glaucoma Patients

Study Overview
=================
Brief Summary
-----------------
Demographic information and a brief medical and concomitant medicine history will be obtained from the glaucoma patient's records. Qualified patients will be asked to complete a questionnaire about their symptoms. Patients will then be scheduled to undergo three standard clinical tests of the ocular surface.

Official Title
-----------------
Prevalence of Ocular Surface Disease in Glaucoma Patients

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of glaucoma; Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Inability to understand trial procedures; Inability to understand Informed Consent; Current use or use within the last 3 months of Restasis, steroids, or topical ocular non-steroidal anti-inflammatory drugs; Punctal plugs; Previous glaucoma, corneal, or conjunctival surgery; Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Ocular hypertension, Dry eye, Ocular surface disease